2021
A retrospective matched cohort single‐center study evaluating outcomes of COVID‐19 and the impact of immunomodulation on COVID‐19‐related cytokine release syndrome in solid organ transplant recipients
Ringer M, Azmy V, Kaman K, Tang D, Cheung H, Azar MM, Price C, Malinis M. A retrospective matched cohort single‐center study evaluating outcomes of COVID‐19 and the impact of immunomodulation on COVID‐19‐related cytokine release syndrome in solid organ transplant recipients. Transplant Infectious Disease 2021, 23: e13556. PMID: 33378571, PMCID: PMC7883059, DOI: 10.1111/tid.13556.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedCase-Control StudiesCohort StudiesComorbidityCOVID-19COVID-19 Drug TreatmentCytokine Release SyndromeFemaleGlucocorticoidsGraft RejectionHeart TransplantationHospitalizationHumansImmunologic FactorsImmunosuppressive AgentsInterleukin-10Interleukin-6Kidney TransplantationLiver TransplantationMaleMiddle AgedReceptors, Interleukin-2Retrospective StudiesSARS-CoV-2Severity of Illness IndexTreatment OutcomeYoung AdultConceptsCytokine release syndromeBody mass indexNon-SOT patientsSOT groupSOT patientsRelease syndromeInterleukin-6COVID-19-related cytokine release syndromeSoluble interleukin-2 receptor levelsControl groupInterleukin-2 receptor levelsSolid organ transplant patientsSolid organ transplant recipientsImpact of immunomodulationInterleukin-10 levelsOrgan transplant recipientsOrgan transplant patientsCritical care needsMulti-center studyCoronavirus disease 2019COVID-19Interleukin levelsIndex hospitalizationTransplant patientsTransplant recipientsCytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19
Azmy V, Kaman K, Tang D, Zhao H, Dela Cruz C, Topal JE, Malinis M, Price CC. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19. Journal Of Clinical Immunology 2021, 41: 738-747. PMID: 33459964, PMCID: PMC7812117, DOI: 10.1007/s10875-020-00949-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBiomarkersCOVID-19COVID-19 Drug TreatmentCytokine Release SyndromeCytokinesDrug Therapy, CombinationFeasibility StudiesFemaleGlucocorticoidsHospitalizationHumansImmunologic FactorsMaleMiddle AgedRetrospective StudiesSARS-CoV-2Severity of Illness IndexTreatment OutcomeYoung AdultConceptsIL-10 levelsIL-6IL-10Disease severityCytokine profileD-dimerTreatment algorithmCritical SARS-CoV-2 infectionCOVID-19SARS-CoV-2 infectionAdministration of tocilizumabAdmission IL-6Maximum oxygen requirementsTocilizumab-treated patientsElevated IL-6Immune-modulating therapyCritical COVID-19Retrospective chart reviewTertiary care centerIL-6 levelsMean IL-6IL-6 inhibitionAdministration of glucocorticoidsRole of cytokinesCytokine elevation
2020
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomesRepurposing antimicrobial stewardship tools in the electronic medical record for the management of COVID-19 patients
Davis MW, McManus D, Koff A, Jaszczur GR, Malinis M, Dela Cruz C, Britto CJ, Price C, Azmy V, Kaman K, Gaston D, Early K, DeWitt M, Song JS, Ortiz C, Juthani-Mehta M, Topal JE. Repurposing antimicrobial stewardship tools in the electronic medical record for the management of COVID-19 patients. Infection Control And Hospital Epidemiology 2020, 41: 1335-1337. PMID: 32507113, PMCID: PMC7308631, DOI: 10.1017/ice.2020.281.Peer-Reviewed Original Research